- Home
- RBCAA vs ETNB Comparison
RBCAA vs ETNB Comparison
Compare RBCAA & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBCAA
- ETNB
- Stock Information
- Founded
- RBCAA 1974
- ETNB 2018
- Country
- RBCAA United States
- ETNB United States
- Employees
- RBCAA N/A
- ETNB N/A
- Industry
- RBCAA Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- RBCAA Finance
- ETNB Health Care
- Exchange
- RBCAA Nasdaq
- ETNB Nasdaq
- Market Cap
- RBCAA 1.3B
- ETNB 1.2B
- IPO Year
- RBCAA 1998
- ETNB 2019
- Fundamental
- Price
- RBCAA $63.82
- ETNB $7.34
- Analyst Decision
- RBCAA
- ETNB Strong Buy
- Analyst Count
- RBCAA 0
- ETNB 10
- Target Price
- RBCAA N/A
- ETNB $27.56
- AVG Volume (30 Days)
- RBCAA 24.7K
- ETNB 2.1M
- Earning Date
- RBCAA 04-24-2025
- ETNB 05-08-2025
- Dividend Yield
- RBCAA 2.81%
- ETNB N/A
- EPS Growth
- RBCAA 12.83
- ETNB N/A
- EPS
- RBCAA 5.14
- ETNB N/A
- Revenue
- RBCAA $330,428,000.00
- ETNB N/A
- Revenue This Year
- RBCAA $1.56
- ETNB N/A
- Revenue Next Year
- RBCAA $3.87
- ETNB N/A
- P/E Ratio
- RBCAA $12.55
- ETNB N/A
- Revenue Growth
- RBCAA 6.29
- ETNB N/A
- 52 Week Low
- RBCAA $46.81
- ETNB $5.99
- 52 Week High
- RBCAA $80.68
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- RBCAA 43.37
- ETNB 39.62
- Support Level
- RBCAA $64.26
- ETNB $7.66
- Resistance Level
- RBCAA $66.15
- ETNB $9.32
- Average True Range (ATR)
- RBCAA 1.39
- ETNB 0.77
- MACD
- RBCAA 0.03
- ETNB -0.04
- Stochastic Oscillator
- RBCAA 20.56
- ETNB 9.04
About RBCAA Republic Bancorp Inc.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through six reportable segments. It has traditional banking which generates the majority of revenue, warehouse, mortgage banking, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).